Xponance Inc. Has $1.25 Million Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX)

Xponance Inc. increased its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 3.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,133 shares of the biopharmaceutical company’s stock after buying an additional 1,437 shares during the period. Xponance Inc.’s holdings in Royalty Pharma were worth $1,249,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in RPRX. Proficio Capital Partners LLC acquired a new stake in Royalty Pharma during the 4th quarter worth approximately $786,000. PNC Financial Services Group Inc. raised its holdings in Royalty Pharma by 53.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,806 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 4,129 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Royalty Pharma by 24.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 818 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Royalty Pharma by 86.0% during the 4th quarter. Corient Private Wealth LLC now owns 46,249 shares of the biopharmaceutical company’s stock worth $1,180,000 after purchasing an additional 21,383 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its holdings in Royalty Pharma by 38.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 475,825 shares of the biopharmaceutical company’s stock worth $12,139,000 after purchasing an additional 132,675 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RPRX has been the subject of several analyst reports. Citigroup restated a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. Wall Street Zen lowered shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Sunday, June 29th. Finally, Morgan Stanley set a $54.00 price target on shares of Royalty Pharma and gave the stock an “overweight” rating in a report on Thursday, July 10th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $48.33.

Royalty Pharma Stock Performance

NASDAQ:RPRX opened at $36.51 on Wednesday. The company has a fifty day moving average of $34.34 and a 200-day moving average of $32.51. The firm has a market capitalization of $20.53 billion, a P/E ratio of 19.74, a P/E/G ratio of 2.41 and a beta of 0.50. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.68. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $36.69.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.07. The company had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. As a group, sell-side analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were paid a $0.22 dividend. The ex-dividend date was Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.41%. Royalty Pharma’s dividend payout ratio is currently 47.57%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.